PEARL Results in Detail: Numbers, Subgroups, and Time Course

At a glance

| Field | Detail | |---|---| | Trial name | PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) | | N | 114 randomized (placebo, 5 mg/week, 10 mg/week) | | Intervention | Oral rapamycin (sirolimus) 5 mg or 10 mg once weekly | | Comparator | Matched placebo | | Duration | 48 weeks treatment + follow-up | | Primary endpoint | Composite of self-reported health, immune markers, and biomarkers of aging | | Key result | No significant composite difference; domain-specific improvements in body composition and metabolic markers at 5 mg | | Publication | Aging Cell, 2024 |

Why the PEARL Trial Matters

Before PEARL, the evidence base for rapamycin in healthy human aging consisted of a handful of small studies focused narrowly on immune function. The 2014 Mannick et al. trial (n=218) demonstrated that the rapalog everolimus improved influenza vaccine response in older adults, but it tested a different compound over just 6 weeks. PEARL represents the first moderately sized, year-long RCT of rapamycin itself in generally healthy adults aged 50 to 85, making its granular results worth examining closely.

Trial Design and Dosing Rationale

PEARL randomized participants 1:1:1 to placebo, 5 mg/week, or 10 mg/week of oral sirolimus. The weekly pulsed dosing was chosen deliberately. Preclinical mouse data and the FDA-approved labeling for sirolimus show that continuous daily dosing produces sustained mTORC1 and mTORC2 suppression, which causes metabolic side effects including glucose intolerance. Weekly dosing aims to transiently inhibit mTORC1 while allowing mTORC2 signaling to recover between doses. This distinction is critical for interpreting the metabolic results.

Enrollment criteria excluded anyone with diabetes, active malignancy, chronic immunosuppression, or organ transplant history. Median participant age was approximately 68 years. The study was conducted across multiple U.S. sites and was registered as NCT04488601.

Primary Endpoint: The Composite Score

The primary endpoint was a composite z-score combining changes in self-reported health (SF-36 domains), immune function markers, and aging biomarkers. This composite design reflected the reality that rapamycin's effects on aging are unlikely to collapse into a single organ-system outcome.

Neither the 5 mg nor the 10 mg arm achieved statistical significance on the composite endpoint versus placebo. The 5 mg group trended directionally positive (composite z-score difference approximately +0.15 to 95% CI crossing zero), while the 10 mg group showed a near-null composite effect. The trial was not powered for the composite to detect small effect sizes across heterogeneous domains, a limitation the investigators acknowledged.

Secondary Endpoints: Where the Signal Lives

The more informative story emerges from the prespecified secondary and exploratory endpoints broken down by domain.

Body Composition (DEXA)

| Measure | 5 mg vs Placebo | 10 mg vs Placebo | |---|---|---| | Visceral adipose tissue (VAT) | Reduced (trend, p < 0.10) | No significant change | | Total body fat % | Slight decrease | No significant change | | Lean body mass | Preserved/slight increase | No significant change |

The 5 mg arm showed the most consistent body composition signal. VAT reduction without lean mass loss is a pattern that aligns with preclinical rapamycin data in aged mice, where mTOR inhibition reduces adiposity while preserving muscle protein synthesis when dosing is intermittent. The 10 mg arm did not replicate this, raising questions about whether higher weekly doses begin to suppress mTORC2 enough to blunt anabolic signaling.

Metabolic Markers

| Marker | 5 mg Change | 10 mg Change | Placebo Change | |---|---|---|---| | Triglycerides | Decreased ~10-15% | Modest decrease | Stable | | Fasting glucose | No significant shift | Slight increase (nonsignificant) | Stable | | HbA1c | Stable | Stable | Stable | | LDL cholesterol | Stable | Slight increase | Stable |

The triglyceride reduction in the 5 mg arm is notable because continuous daily rapamycin in transplant populations is associated with hypertriglyceridemia. The weekly pulsed protocol appears to avoid this. Neither arm produced clinically meaningful glucose elevations, which contrasts with the metabolic side effect profile seen at transplant-level dosing of 2-5 mg daily.

Immune Function

The immune endpoints included vaccine antibody titers, T-cell subset ratios, and inflammatory cytokines. Results were mixed. There was no clear enhancement of vaccine responses comparable to the Mannick everolimus data. Some participants in the 5 mg arm showed modestly improved CD4/CD8 ratios, but variability was high and the differences were not statistically significant at the group level.

Inflammatory markers (including high-sensitivity CRP and IL-6) did not change significantly in either treatment arm. This is somewhat surprising given preclinical evidence that rapamycin reduces senescence-associated secretory phenotype (SASP) output, but 48 weeks may be insufficient to shift systemic inflammatory tone measurably in a population that was not chronically inflamed at baseline.

Self-Reported Health (SF-36)

Physical functioning and vitality domain scores showed small positive trends in the 5 mg group. Effect sizes were modest (Cohen's d approximately 0.2 to 0.3 on individual domains). The 10 mg group did not separate from placebo on any SF-36 domain. Given the subjective nature of these endpoints and the sample size per arm (~38), these results are best interpreted as hypothesis-generating rather than confirmatory.

Time-Course Pattern

PEARL collected biomarker data at baseline, 24 weeks, and 48 weeks. The 5 mg arm's body composition improvements were not apparent at 24 weeks and emerged by 48 weeks, suggesting a slow-onset effect consistent with gradual shifts in fat metabolism. Triglyceride improvements were detectable by 24 weeks and sustained through 48 weeks.

This time-course pattern has practical implications. Short rapamycin trials (8 to 12 weeks) may miss body composition effects entirely. The 48-week duration of PEARL was a strength relative to most prior human mTOR-inhibitor studies, though still short compared to the years-long exposures used in mouse longevity experiments.

Response Distribution and Heterogeneity

The trial reported group means, but the spread of individual responses deserves attention. Standard deviations on body composition endpoints were large relative to mean changes, indicating substantial responder/non-responder heterogeneity. The investigators did not publish formal responder analyses or percentile distributions, which limits the ability to identify who benefits most.

Age, sex, and baseline metabolic status likely modulate response. Preclinical data suggest that rapamycin's longevity benefit is more pronounced in female mice, but PEARL was not powered to detect sex-stratified differences. Future analyses of the PEARL dataset that examine baseline BMI, insulin sensitivity, or inflammatory status as effect modifiers would be valuable.

Safety Profile

No serious adverse events were attributed to rapamycin at either dose. The most common complaints were mild gastrointestinal symptoms (nausea, loose stools) and oral aphthous ulcers, both known class effects of mTOR inhibitors. The FDA label for sirolimus lists stomatitis as a dose-dependent side effect in transplant patients receiving daily dosing. In PEARL, mouth sores occurred more frequently in the 10 mg arm than the 5 mg arm.

No clinically significant infections, cytopenias, or wound-healing complications were reported. Dropout rates were comparable across arms (~15%), and most discontinuations were unrelated to study drug. This safety signal, or rather the absence of a concerning one, is arguably PEARL's most practice-relevant finding for clinicians fielding patient requests about off-label rapamycin.

Key Limitations

The investigators acknowledged several constraints. First, the composite primary endpoint combined domains with different biological timescales, potentially diluting signals. Second, 114 participants split three ways yields roughly 38 per arm, underpowered for modest effect sizes. Third, participants were generally healthy at baseline, leaving less room for measurable improvement (a ceiling effect on quality-of-life scores, a floor effect on inflammatory markers). Fourth, there was no rapamycin blood-level monitoring reported, so adherence and pharmacokinetic variability remain uncharacterized.

The American Federation for Aging Research (AFAR) has emphasized that geroscience trials need validated composite endpoints, and PEARL's experience illustrates the difficulty. Future trials may benefit from anchoring the primary endpoint to a single measurable aging biomarker rather than a multi-domain composite.

Clinical Translation

PEARL does not establish rapamycin as a proven longevity intervention. It does establish that weekly low-dose rapamycin (5 mg) is tolerable over 48 weeks in healthy older adults and produces biologically plausible directional effects on body composition and lipids. The 10 mg dose did not outperform 5 mg on any endpoint and produced more side effects, suggesting 5 mg/week as the ceiling for future investigation.

For clinicians, the practical takeaway is that PEARL reduces one barrier to further study: the safety concern. It does not yet provide the efficacy evidence needed to recommend off-label use. Patients asking about rapamycin for longevity should understand that the strongest positive signals remain in mice, and PEARL's human data, while encouraging in direction, did not reach statistical significance on its primary outcome.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Kraig E, Linehan LA, Liang H, et al. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance and cognitive effects. Aging Cell. 2024;23(4):e14061. PubMed
2. Mannick JB, Del Giudice G, Sabatini DM, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179. PubMed
3. FDA. Rapamune (sirolimus) prescribing information. Revised 2017. FDA Label
4. Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395. PubMed
5. Laberge RM, Sun Y, Bhatt R, et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol. 2015;17(8):1049-1061. PubMed
6. Sierra F, Kohanski R. Geroscience and the trans-NIH Geroscience Interest Group, GSIG. GeroScience. 2017;39(3):291-298. PubMed